RxDoctor Payments Data

Katelynn Dickerson, PA

Physician Assistant · Brigham City, UTNPI 1972058048

Payments from drug & device makers

$957in general payments, 2019–2025

Across 55 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$195
  • AbbVie$154
  • AstraZeneca$75
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$73
  • Organon$50
  • Boston Scientific$50
  • plus $360 from 15 others

What the payments were for

  • Food & beverage$94599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$957 in reported general payments places this provider in the 70th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$15,828
Medicare patients
77
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$27,839
JardianceEmpagliflozin16$21,375
EliquisApixaban15$16,037
FarxigaDapagliflozin Propanediol11$11,028
TrulicityDulaglutide11$10,928
Omeprazole62$1,246
Bupropion XlBupropion Hcl41$1,161
Fluticasone Propionate31$1,003
Sertraline Hcl43$666
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$634
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide37$582
Duloxetine Hcl19$573
Gabapentin27$567
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$561
Levothyroxine Sodium55$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$27,83916 claims
PfizerEliquis$34$16,03715 claims
AstraZenecaFarxiga$75$11,02811 claims
Lilly USA, LLCTrulicity$13$10,92811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Brigham City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →